Plain-English translation of NCT06911255 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether tremelimumab and durvalumab—two immunotherapy medications that help your immune system fight cancer—work better when combined with transarterial chemoembolization (TACE), a procedure that delivers chemotherapy directly to liver tumors. The study will enroll 24 patients with advanced liver cancer to see if this combination is safe and effective at slowing or stopping cancer growth.
Current treatments for advanced liver cancer that cannot be surgically removed have limited effectiveness. Researchers believe that combining this medication with a targeted liver procedure may give patients better outcomes by attacking the cancer from multiple angles at once.
You likely qualify if…
You likely don't qualify if…
You will receive intravenous infusions of the two immunotherapy medications, followed by the TACE procedure about 1–2 weeks later. After that, you will continue receiving the immunotherapy infusion every 4 weeks, with additional TACE procedures performed as needed based on how your cancer responds. Throughout the study, you will have regular visits for imaging scans and blood tests to monitor how well the treatment is working and to watch for any side effects. The study will track your progress for at least 48 weeks, then continue monitoring you periodically until your cancer progresses.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
South Korea
Phase
Safety & dosing / Early efficacy
Sponsor
Yoon Jun Kim
Collaborators
AstraZeneca
Enrollment target
~24 participants
Started
April 2025
Primary completion
March 2028
Age range
19 Years and older
Last updated on clinicaltrials.gov in May 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yoon Jun Kim, MD, PhD
Seoul National University Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.